Company intelligence / Profile preview

Oceanium

Dunbeg, Scotland, United Kingdom

Ownership: Private
Development stage: Other

Overview

Oceanium has developed a clinically proven, low-dose seaweed prebiotic (OCEAN ACTIVES H+) demonstrating improved gut health—including reduced harmful bacteria and increased butyrate and anti-inflammatory response—with minimal digestive side effects in a published 12-week randomized trial. The company has also achieved commercial validation for its biodegradable seaweed-based ink and other sustainable ingredients.

Therapeutic areas: ImmunologyCardiovascularEndocrinologyGastroenterologyDermatology
Modalities: Plant-based compoundNutritional ingredientPrebiotic
Industry: Food & Nutrition

Partnerships

European Commission – CINEA, Research Executive Agency (REA)Innovate UKScottish Enterprise

Beyond the preview

Go deeper on Oceanium.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oceanium.

Explore the full profile